The global cell harvesting systems market size was valued USD 3.17 billion in 2016 and is expected to grow at a CAGR of 13.9% over the forecast period. Major factors driving the growth of this industry are increasing demand for stem cell-based therapy and rising investment in clinical research, owing to its potential benefits in regenerative medicine.
Increasing aging population and rising prevalence of chronic conditions, such as cardiovascular diseases, are further expected to contribute to the demand for stem cell-based therapy, thereby propelling the market. There has been a significant rise in stem cell-based research over the past decade, which is driving the demand for stem cell harvesting for research. For instance, the National Institutes of Health (NIH), a primary agency for biomedical and public healthcare research in the U.S., invested USD 1.49 billion in stem cell research in 2016, which was an increase of approximately 5.0% from 2015.
The rising transplantation rate and growing demand for stem cell banking are also some of the factors responsible for the rising requirement of harvesting across the globe. The new sources of stem cells, such as umbilical cord, adipose tissue, and embryonic stem cells, exhibit tremendous potential for cancer treatment and development of regenerative products, which drives research associated with these sources.
However, ethical issues related to embryonic stem cells and unapproved stem cell therapy provided by healthcare providers in unregulated regions such as Latin America and Asia Pacific are expected to limit the growth of this market over the forecast period.
This technique is used to retrieve stem cells from umbilical cord, bone marrow, peripheral blood, adipose tissue, and other sources. The peripheral blood segment held the largest market share in 2016 and is expected to maintain it over the forecast period. This can be attributed to the high use of peripheral blood in stem cell transplants and the growing use of peripheral blood in stem cell research.
Adipose tissue is expected to witness the fastest growth owing to the retrieval of a higher number of stem cells from liposuction and their potential use in regenerative medicine. Umbilical cord is also expected to witness lucrative growth owing to its increasing use in transplantation and potential use in other therapies.
On the basis of end-use, the market is segmented into hospitals, clinics, academic institutes, and R&D centers. Hospitals held the largest share and is expected to continue the dominance over the forecast period, as the majority of stem cell harvesting for transplantation & research is undertaken in hospitals.
Academic institutes and R&D centers are expected to witness the fastest growth, owing to growing investment in research by universities and biopharmaceutical companies. Rising demand for regenerative medicine and stem cell-based therapies is further expected to contribute toward the growth of research in academic institutes and R&D centers.
Europe and North America spearheaded the market as of 2016, by contributing over 74.0% to the overall revenue. The majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.
In 2016, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second-largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to the rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy. Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and an increase in the aging population can be attributed to the increasing demand for these therapies in these countries.
Primary participants profiled for the market are Argos Technologies, Inc.; Perkin Elmer, Inc.; Brand GmBh + CO KG; Arthrex, Inc.; Avita Medical; Tomtec; Terumo Corporation; Teleflex, Inc.; and Bertin.
Companies such as Terumo Corporation offer a wide range of products including apheresis systems and harvesters. In September 2016, Terumo BCT formed a strategic collaboration with Cognate Bioservices-a bioservice contract organization-for developing immunotherapy and other related products and increasing the use of the quantum systems in manufacturing cell therapy products.
Report Attribute |
Details |
Market size value in 2020 |
USD 5.3 billion |
Revenue forecast in 2025 |
USD 10.2 billion |
Growth Rate |
CAGR of 13.9% from 2017 to 2025 |
Base year for estimation |
2015 |
Historical data |
2014 - 2016 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD Million and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Application, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; China; Japan; Mexico; Brazil; South Africa; Saudi Arabia |
Key companies profiled |
Argos Technologies, Inc.; Perkin Elmer, Inc.; Brand GmBh + CO KG; Arthrex, Inc.; Avita Medical; Tomtec; Terumo Corporation; Teleflex, Inc.; Bertin. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global cell harvesting system market on the basis of application, end use, and region:
Application Outlook (Revenue, USD Million, 2014 - 2025)
Umbilical Cord
Bone Marrow
Peripheral Blood
Adipose tissue
Other sources
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Hospitals
Clinics
Academic institutes
R&D centers
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
China
Japan
Latin America
Brazil
Mexico
MEA
South Africa
Saudi Arabia
b. The global cell harvesting system market size was estimated at USD 4.6 billion in 2019 and is expected to reach USD 5.3 billion in 2020.
b. The global cell harvesting system market is expected to grow at a compound annual growth rate of 13.9% from 2017 to 2025 to reach USD 10.2 billion by 2025.
b. North America dominated the cell harvesting system market with a share of 35.1% in 2019. This is attributable to rise in the number of stem cell clinical trials, and stem cell transplantation in the region.
b. Some key players operating in the cell harvesting system market include Argos Technologies, Inc.; Perkin Elmer, Inc.; Brand GmBh + CO KG; Arthrex, Inc.; Avita Medical; Tomtec; Terumo Corporation; Teleflex, Inc.; and Bertin.
b. Key factors that are driving the market growth include a rise in stem cell transplantation, an increase in stem cell research, and rising demand for stem cell therapy.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.